JP2018203747A - シクロデキストリンを使用するための方法 - Google Patents
シクロデキストリンを使用するための方法 Download PDFInfo
- Publication number
- JP2018203747A JP2018203747A JP2018150978A JP2018150978A JP2018203747A JP 2018203747 A JP2018203747 A JP 2018203747A JP 2018150978 A JP2018150978 A JP 2018150978A JP 2018150978 A JP2018150978 A JP 2018150978A JP 2018203747 A JP2018203747 A JP 2018203747A
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- cholesterol
- dkd
- cell
- diabetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
患者血清および腎臓生検材料。血清サンプルは、10人の健康なコントロールおよびフィンランド糖尿病性腎症研究(FinnDiane)のT1Dを有する20人の患者から得た。T1Dは、40歳前の糖尿病の発病および診断の1年以内に開始された永久的インスリン治療として定義した。尿アルブミン排出速度(AER)は、正常AER(<30mg/24時間)、ミクロアルブミン尿(≧30<300mg/24時間)、およびマクロアルブミン尿(≧300mg/24時間)として定義した。空腹時グルコース値は、Hemocueデバイス(Hemocue、フィンランド)を使用して測定した。血清脂質は、Konelabアナライザー(Thermo Scientific、フィンランド)により決定した。他の生化学的分析は、認可された病院検査室(HUSLAB、ヘルシンキ)において実行した。糸球体mRNA発現プロファイルについては、腎臓生検組織は、インフォームドコンセントを得た後に70人の南西部のアメリカインディアンから得た。移植前、健康な生体ドナー(n=32)、膜性腎症(n=21)、および巣状分節性糸球体硬化症(n=18)患者由来のヒト腎生検材料は、European Renal cDNA Bankから得た。
臨床検査室測定および患者集団。発明者らは、血清サンプルの収集の時に臨床的特徴に基づいて3つの群に分けた30人の男性対象について研究した。研究対象に、
1)糖尿病性腎疾患を有していない(DKD−)患者として定義される、T1D、正常アルブミン尿、および正常クレアチニンを有する10人の患者、
2)糖尿病性腎疾患を有する(DKD+)患者として定義される、T1D、アルブミン尿、およびクレアチニン異常を有する10人の患者、
3)10人の健康なコントロールを含めた。3つの群は、年齢、総コレステロール、HDLコレステロール、LDLコレステロール、およびトリグリセリドについて有意に異なっていなかった。すべての患者は、レニン−アンギオテンシン−アルドステロン系を遮断するための作用物質を服用していた。糖尿病の持続期間、空腹時血糖値、およびHbA1Cは、DKD+およびDKD−患者の間で有意に異なっていなかった。平均推定糸球体濾過率(eGFR)は、DKD−において101ml/分/1.73m2、Cにおいて97ml/分/1.73m2、およびDKD+群において43ml/分/1.73m2であった。DKD(平均eGFR 98ml/分/1.73m2)を有する5人の患者から7年前から収集していた血清を、選択した実験において利用した。
強力なコレステロール受容体である2−ヒドロキシプロピル−β−シクロデキストリン(2−HPβCD)は、インビボおよびインビトロにおいて、コレステロールを捕捉し、かつ、コレステロール依存性の損傷から糖尿病、糖尿病前症、メタボリックシンドローム、および肥満によって冒される任意の細胞を防御するのに有効な方法である。
Claims (1)
- 糖尿病(1型)、糖尿病(2型)、糖尿病前症、肥満、メタボリックシンドローム、糖尿病性腎症、糖尿病性腎疾患、糖尿病性ニューロパシー、糖尿病性網膜症、糖尿病関連性の微小血管合併症、糖尿病関連性の大血管合併症、アテローム性動脈硬化症、末梢血管疾患、冠動脈疾患、鬱血性心不全、心肥大、心筋梗塞、内皮機能不全および高血圧、発作、脳血管発作、心筋梗塞、心臓発作、心臓血管に関する事故、脂肪肝、脂肪性肝炎、NASH、ならびにインスリン抵抗性から選択される状態に罹患している患者における細胞または細胞の形質膜における脂質含有量を低下させるための方法において、細胞の脂質含有量を低下させる化合物の有効量を患者に対して投与するステップを含むことを特徴とする方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021103893A JP2021155436A (ja) | 2012-04-13 | 2021-06-23 | シクロデキストリンを使用するための方法 |
JP2023146755A JP2023178518A (ja) | 2012-04-13 | 2023-09-11 | シクロデキストリンを使用するための方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261624087P | 2012-04-13 | 2012-04-13 | |
US61/624,087 | 2012-04-13 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015505963A Division JP6491089B2 (ja) | 2012-04-13 | 2013-04-12 | シクロデキストリンを使用するための方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021103893A Division JP2021155436A (ja) | 2012-04-13 | 2021-06-23 | シクロデキストリンを使用するための方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018203747A true JP2018203747A (ja) | 2018-12-27 |
JP2018203747A5 JP2018203747A5 (ja) | 2019-05-16 |
Family
ID=49328287
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015505963A Active JP6491089B2 (ja) | 2012-04-13 | 2013-04-12 | シクロデキストリンを使用するための方法 |
JP2018150978A Pending JP2018203747A (ja) | 2012-04-13 | 2018-08-10 | シクロデキストリンを使用するための方法 |
JP2021103893A Pending JP2021155436A (ja) | 2012-04-13 | 2021-06-23 | シクロデキストリンを使用するための方法 |
JP2023146755A Pending JP2023178518A (ja) | 2012-04-13 | 2023-09-11 | シクロデキストリンを使用するための方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015505963A Active JP6491089B2 (ja) | 2012-04-13 | 2013-04-12 | シクロデキストリンを使用するための方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021103893A Pending JP2021155436A (ja) | 2012-04-13 | 2021-06-23 | シクロデキストリンを使用するための方法 |
JP2023146755A Pending JP2023178518A (ja) | 2012-04-13 | 2023-09-11 | シクロデキストリンを使用するための方法 |
Country Status (8)
Country | Link |
---|---|
US (4) | US10195227B2 (ja) |
EP (2) | EP4299121A2 (ja) |
JP (4) | JP6491089B2 (ja) |
CN (2) | CN104244956B (ja) |
CA (1) | CA2870316C (ja) |
ES (1) | ES2959119T3 (ja) |
MX (2) | MX371073B (ja) |
WO (1) | WO2013155485A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021155436A (ja) * | 2012-04-13 | 2021-10-07 | エル アンド エフ リサーチ,リミテッド ライアビリティー カンパニー | シクロデキストリンを使用するための方法 |
WO2023033276A1 (ko) * | 2021-09-01 | 2023-03-09 | 주식회사 레나투스 | 감마-사이클로덱스트린 중합체를 포함하는 약학적 조성물 및 이의 용도 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2899756T3 (es) | 2013-03-12 | 2022-03-14 | Primal Therapies Inc | Composición dental que comprende quelante y base |
JP6418911B2 (ja) * | 2014-11-18 | 2018-11-07 | 学校法人中部大学 | Glp−1分泌促進剤 |
JP2018517046A (ja) | 2015-06-10 | 2018-06-28 | ビテス, インコーポレイテッド | ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法 |
CN105395549A (zh) * | 2015-11-03 | 2016-03-16 | 天津医科大学总医院 | 烟酸的新用途 |
WO2018051298A1 (en) * | 2016-09-19 | 2018-03-22 | Aten Porus Lifesciences | Cyclodextrin based polymers, methods, compositions and applications thereof |
WO2018075622A1 (en) * | 2016-10-19 | 2018-04-26 | University Of Miami | Materials and methods for modulating insulin signaling and preserving podocyte function |
CN107982546A (zh) * | 2017-12-05 | 2018-05-04 | 中国药科大学 | 基于主客体相互作用的酸敏感超分子纳米粒及其应用 |
US11925659B2 (en) | 2018-10-29 | 2024-03-12 | Cyclo Therapeutics, Inc. | Methods for treating Alzheimer's disease |
CN113490691A (zh) | 2019-01-03 | 2021-10-08 | 劣势者药物有限公司 | 环糊精二聚体、其组合物及其用途 |
WO2020213010A1 (en) * | 2019-04-16 | 2020-10-22 | Celagenex Research (India) Pvt. Ltd. | Synergistic lipid controlling compositions |
AU2021333902A1 (en) * | 2020-08-27 | 2023-03-16 | Beren Therapeutics P.B.C. | Methods for the treatment of cholesterol crystal embolization with cyclodextrins |
US20230302042A1 (en) * | 2020-08-27 | 2023-09-28 | Beren Therapeutics P.B.C. | Methods for the prevention of cholesterol crystal embolization with cyclodextrins |
WO2022047249A1 (en) * | 2020-08-27 | 2022-03-03 | Beren Therapeutics P.B.C. | Methods for the treatment of cardiovascular disease with cyclodextrins |
CN112089843B (zh) * | 2020-10-13 | 2022-11-04 | 合肥工业大学 | 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用 |
CN113295793B (zh) * | 2021-05-20 | 2022-11-04 | 复旦大学附属中山医院 | 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用 |
WO2023156966A1 (en) | 2022-02-18 | 2023-08-24 | Beren Therapeutics P.B.C. | Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004323443A (ja) * | 2003-04-25 | 2004-11-18 | Tokai Univ | 抗血栓薬 |
JP2008523096A (ja) * | 2004-12-10 | 2008-07-03 | スーパージェン インコーポレイテッド | デシタビン医薬製剤 |
WO2009142988A2 (en) * | 2008-05-14 | 2009-11-26 | Florida Atlantic University | Chitin micro-particles as an adjuvant |
JP2010506942A (ja) * | 2006-10-20 | 2010-03-04 | イコス・コーポレイション | Chk1阻害剤の組成物 |
WO2011043630A2 (ko) * | 2009-10-08 | 2011-04-14 | (주)송호바이오메드 | 고 수용성 2-하이드록시프로필-베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물 |
WO2012012473A1 (en) * | 2010-07-19 | 2012-01-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of delta tocopherol for the treatment of lysosomal storage disorders |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0672100B2 (ja) | 1989-11-15 | 1994-09-14 | 株式会社上野製薬応用研究所 | 利尿剤 |
US5840713A (en) * | 1995-04-03 | 1998-11-24 | Weisz; Paul B. | Therapy for tissue membrane insufficiency |
WO2000025803A1 (fr) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Preparations contenant une proteine betacelluline |
US6756504B2 (en) * | 2000-04-19 | 2004-06-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingolipids |
US20040121983A1 (en) * | 2002-08-12 | 2004-06-24 | Council Of Scientific And Industrial Research | Method for treating leishmaniasis using methyl-beta-cyclodextrin |
ATE442165T1 (de) | 2002-08-19 | 2009-09-15 | Art Jen Complexus Inc | Zusammensetzungen mit einem nahrungsfett- komplexbildner und anwendungsverfahren |
US20060148721A1 (en) * | 2003-06-06 | 2006-07-06 | Erondu Ngozi E | Combination therapy for the treatment of dyslipidemia |
US9200245B2 (en) | 2003-06-26 | 2015-12-01 | Seng Enterprises Ltd. | Multiwell plate |
US7393826B2 (en) * | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
US7276351B2 (en) | 2003-09-10 | 2007-10-02 | Seahorse Bioscience | Method and device for measuring multiple physiological properties of cells |
US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
CN1282425C (zh) * | 2004-06-22 | 2006-11-01 | 王美岭 | 苹果醋营养品及其生产方法 |
JP2006191830A (ja) * | 2005-01-12 | 2006-07-27 | Unitika Ltd | 脂肪の蓄積を抑制する食品 |
AU2006208108A1 (en) | 2005-01-27 | 2006-08-03 | Erimos Pharmaceuticals Llc | Oral formulations for delivery of catecholic butanes including NDGA compounds |
WO2007056435A2 (en) | 2005-11-08 | 2007-05-18 | The General Hospital Corporation | Dynamin mediated diseases and associated methods and products |
EP1894924A1 (en) * | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
WO2010042202A1 (en) | 2008-10-07 | 2010-04-15 | Fibrogen, Inc. | Methods for treatment of podocyte injury |
CA2740003A1 (en) | 2008-10-10 | 2010-04-15 | Limerick Biopharma, Inc. | Pyrone analogs for therapeutic treatment |
US8202702B2 (en) | 2008-10-14 | 2012-06-19 | Seahorse Bioscience | Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision |
US8263413B1 (en) | 2008-10-17 | 2012-09-11 | Andrew S Hansen | Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry |
WO2010054167A2 (en) | 2008-11-06 | 2010-05-14 | University Of Miami | Limited proteolysis of cd2ap and progression of renal disease |
WO2010103823A1 (ja) | 2009-03-12 | 2010-09-16 | パナソニック株式会社 | 画像表示装置および画像表示方法 |
WO2011057172A1 (en) | 2009-11-06 | 2011-05-12 | University Of Miami | Podocyte specific assays and uses thereof |
US8372877B2 (en) * | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
CA2852904C (en) | 2010-10-19 | 2019-01-08 | University Of Miami | Assays, methods and kits for predicting renal disease and personalized treatment strategies |
MX371073B (es) * | 2012-04-13 | 2020-01-15 | L&F Res Llc | Método para utilizar ciclodextrina. |
-
2013
- 2013-04-12 MX MX2014012200A patent/MX371073B/es active IP Right Grant
- 2013-04-12 CN CN201380019867.5A patent/CN104244956B/zh active Active
- 2013-04-12 WO PCT/US2013/036484 patent/WO2013155485A2/en active Application Filing
- 2013-04-12 CA CA2870316A patent/CA2870316C/en active Active
- 2013-04-12 JP JP2015505963A patent/JP6491089B2/ja active Active
- 2013-04-12 CN CN202010200900.6A patent/CN111419870A/zh active Pending
- 2013-04-12 EP EP23183457.3A patent/EP4299121A2/en active Pending
- 2013-04-12 ES ES13775223T patent/ES2959119T3/es active Active
- 2013-04-12 US US14/391,236 patent/US10195227B2/en active Active
- 2013-04-12 MX MX2020000205A patent/MX2020000205A/es unknown
- 2013-04-12 EP EP13775223.4A patent/EP2836221B1/en active Active
-
2018
- 2018-08-10 JP JP2018150978A patent/JP2018203747A/ja active Pending
- 2018-12-20 US US16/227,018 patent/US10980828B2/en active Active
-
2021
- 2021-01-22 US US17/155,545 patent/US20210228616A1/en not_active Abandoned
- 2021-06-23 JP JP2021103893A patent/JP2021155436A/ja active Pending
-
2022
- 2022-09-21 US US17/949,672 patent/US20230338412A1/en active Pending
-
2023
- 2023-09-11 JP JP2023146755A patent/JP2023178518A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004323443A (ja) * | 2003-04-25 | 2004-11-18 | Tokai Univ | 抗血栓薬 |
JP2008523096A (ja) * | 2004-12-10 | 2008-07-03 | スーパージェン インコーポレイテッド | デシタビン医薬製剤 |
JP2010506942A (ja) * | 2006-10-20 | 2010-03-04 | イコス・コーポレイション | Chk1阻害剤の組成物 |
WO2009142988A2 (en) * | 2008-05-14 | 2009-11-26 | Florida Atlantic University | Chitin micro-particles as an adjuvant |
WO2011043630A2 (ko) * | 2009-10-08 | 2011-04-14 | (주)송호바이오메드 | 고 수용성 2-하이드록시프로필-베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물 |
WO2012012473A1 (en) * | 2010-07-19 | 2012-01-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of delta tocopherol for the treatment of lysosomal storage disorders |
Non-Patent Citations (1)
Title |
---|
J.BIOL.CHEM., vol. 270(29), JPN6017001676, 1995, pages 17250 - 17256, ISSN: 0004449824 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021155436A (ja) * | 2012-04-13 | 2021-10-07 | エル アンド エフ リサーチ,リミテッド ライアビリティー カンパニー | シクロデキストリンを使用するための方法 |
WO2023033276A1 (ko) * | 2021-09-01 | 2023-03-09 | 주식회사 레나투스 | 감마-사이클로덱스트린 중합체를 포함하는 약학적 조성물 및 이의 용도 |
Also Published As
Publication number | Publication date |
---|---|
ES2959119T3 (es) | 2024-02-20 |
MX2014012200A (es) | 2015-06-17 |
JP6491089B2 (ja) | 2019-03-27 |
CN104244956A (zh) | 2014-12-24 |
EP2836221A4 (en) | 2016-07-27 |
US20150065457A1 (en) | 2015-03-05 |
US20210228616A1 (en) | 2021-07-29 |
US10195227B2 (en) | 2019-02-05 |
US10980828B2 (en) | 2021-04-20 |
MX2020000205A (es) | 2022-06-06 |
CN104244956B (zh) | 2020-04-17 |
WO2013155485A2 (en) | 2013-10-17 |
US20190262385A1 (en) | 2019-08-29 |
JP2023178518A (ja) | 2023-12-15 |
JP2015512949A (ja) | 2015-04-30 |
EP2836221B1 (en) | 2023-07-05 |
CA2870316C (en) | 2022-04-19 |
WO2013155485A3 (en) | 2013-12-19 |
EP2836221A2 (en) | 2015-02-18 |
CN111419870A (zh) | 2020-07-17 |
EP4299121A2 (en) | 2024-01-03 |
MX371073B (es) | 2020-01-15 |
US20230338412A1 (en) | 2023-10-26 |
JP2021155436A (ja) | 2021-10-07 |
CA2870316A1 (en) | 2013-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6491089B2 (ja) | シクロデキストリンを使用するための方法 | |
JP2018203747A5 (ja) | ||
AU2016246524B2 (en) | Pharmaceutical compositions for combination therapy | |
US20230285329A1 (en) | Methods and Compositions for the Treatment of Steatosis-Associated Disorders | |
ES2307729T3 (es) | Modulacion de un perfil lipidico con esteroides y agonistas de ppar alfa. | |
US20190100758A1 (en) | Methods of Treating Colorectal Cancer | |
AU2014229985A1 (en) | Methods of treating colorectal cancer | |
KR20190044666A (ko) | Fxr 작용제들의 조합물 | |
Astrike-Davis et al. | Targeting cellular senescence as a novel treatment for osteoarthritis | |
Yang et al. | Repeated administration of adipose-derived mesenchymal stem cells added on beneficial effects of empagliflozin on protecting renal function in diabetic kidney disease rat | |
US10758551B2 (en) | Methods and compositions for treating pancreatitis | |
Zhou et al. | Artemisinin inhibits glycosaminoglycan chain synthesizing gene expression but not proliferation of human vascular smooth muscle cells | |
US10190119B2 (en) | Mitochondrial phosphate carrier targets for treating soft-tissue calcification | |
Ma et al. | Pentoxifylline protects against loss of function and renal interstitial fibrosis in chronic experimental partial ureteral obstruction | |
WO2018027149A1 (en) | Methods of treating alport syndrome | |
Elrggal et al. | Diabesity and the Kidney | |
US20040068006A1 (en) | Method for preventing acute renal failure | |
KR20210015849A (ko) | 트로피펙소르 및 세니크리비록을 포함하는 조합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190401 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190820 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200428 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200727 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200928 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201028 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210224 |